LY2127399
13653
Phase 3 small_molecule completed
Quick answer
LY2127399 for Systemic Lupus Erythematosus is a Phase 3 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Systemic Lupus Erythematosus
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed